Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Head and neck cancer]

Y Inuyama1, S Fukuda, N Satoh

  • 1Dept. of Otolaryngology, Hokkaido University School of Medicine, Sapporo, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 14, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stimulatory effect of insulin on H+-ATPase in the proximal tubule via the Akt/mTORC2 pathway.

Physiology international·2020
Same author

AmAMP1 from Acropora millepora and damicornin define a family of coral-specific antimicrobial peptides related to the Shk toxins of sea anemones.

Developmental and comparative immunology·2020
Same author

Phylogenetic Relationships between Solitary and Colonial Ascidians, as Inferred from the Sequence of the Central Region of their Respective 18S rDNAs.

The Biological bulletin·2018
Same author

Muscle determinants in the ascidian egg are inactivated by UV irradiation and the inactivation is partially rescued by injection of maternal mRNAs.

Roux's archives of developmental biology : the official organ of the EDBO·2017
Same author

Mechanisms of Specification in Ascidian Embryos.

The Biological bulletin·2017
Same author

The transcriptomic response of the coral Acropora digitifera to a competent Symbiodinium strain: the symbiosome as an arrested early phagosome.

Molecular ecology·2016
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Nedaplatin (NDP) shows effectiveness in head and neck cancer, with a 42% response rate. New agents like taxol and taxotere are also promising, but toxicity remains a concern.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Nedaplatin (NDP), a cisplatin derivative, is commercially available and effective for head and neck cancers.
  • Several new chemotherapeutic agents, including S-1, taxotere (TXT), taxol (TXL), topotecan, amonafide, vinorelbine, and thymitaq, have been evaluated for head and neck cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy of nedaplatin (NDP) in head and neck cancer.
  • To assess the response rates of new chemotherapeutic agents and combination therapies for head and neck cancer.
  • To explore the potential of concurrent chemoradiotherapy using novel agents.

Main Methods:

  • Phase II study of nedaplatin (NDP) in 90 evaluable patients.
  • Clinical trials of combination chemotherapy, including NDP + 5-FU.
  • Evaluation of single-agent efficacy for taxol (TXL), taxotere (TXT), topotecan, amonafide, vinorelbine, and thymitaq.

Related Experiment Videos

  • Assessment of combination chemotherapy response rates (e.g., TXL + CDDP, TXT + CDDP + 5-FU).
  • Investigation of concurrent chemoradiotherapy protocols (e.g., 5-FU + HU + TXL + RT).

    • Main Results:

    • Nedaplatin (NDP) achieved a 42% response rate (11 CR, 27 PR) in head and neck cancer patients.
    • Taxol (TXL) showed response rates of 26-37%, and taxotere (TXT) 27-41%.
    • Combination chemotherapy yielded high response rates: TXL + CDDP (33-71%), TXT + CDDP (78%), TXT + CDDP + 5-FU (75%).
    • Concurrent chemoradiotherapy protocols demonstrated responsiveness in squamous cell carcinoma of the head and neck.

    Conclusions:

    • Nedaplatin (NDP) is an effective agent for head and neck cancer.
    • Newer agents like taxol (TXL) and taxotere (TXT) demonstrate significant efficacy.
    • Combination chemotherapy and concurrent chemoradiotherapy show promise but require management of toxicities like stomatitis and bone marrow suppression.